Evidence map›Paper›PMID 37572954›Full record

ArticleNeuropharmacology2023

PYY

A Caffrey, E Lavecchia, R Merkel, Y Zhang, K S Chichura, M R Hayes, R P Doyle, H D Schmidt

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

A CaffreyDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
E LavecchiaDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
R MerkelDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
Y ZhangDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
K S ChichuraDepartment of Chemistry, Syracuse University, NY, 13244, USA.
M R HayesDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.
R P DoyleDepartment of Chemistry, Syracuse University, NY, 13244, USA; Departments of Medicine and Pharmacology, State University of New York, Upstate Medical University, Syracuse, NY, 13210, USA.
H D SchmidtDepartment of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA, 19104, USA; Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA. Electronic address: hschmidt@nursing.upenn.edu.
University of Pennsylvania · USSUNY Upstate Medical University · USSyracuse University · US

Funding

Amylin Modulates Food RewardR01DK105155 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HAYES, MATTHEW R · 2016 to 2025
$4.1M
The role of central GLP-1 receptors in animal models of cocaine addictionR01DA037897 · NIDA · UNIVERSITY OF PENNSYLVANIA · PI SCHMIDT, HEATH D · 2015 to 2023
$3.5M
Second generation GLP-1 agonists without nausea/emesis side effectsR01DK128443 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DE JONGHE, BART C, DOYLE, ROBERT P · 2021 to 2024
$2.4M
NIDA NIH HHS R01 DA037897NIDDK NIH HHS R01 DK105155NIDDK NIH HHS R01 DK128443
6 · The paper itself

Abstract

More effective treatments for fentanyl use disorder are urgently needed. An emerging literature indicates that glucagon-like peptide-1 receptor (GLP-1R) agonists attenuate voluntary opioid taking and seeking in rodents. However, GLP-1R agonists produce adverse malaise-like effects that may limit patient compliance. Recently, we developed a dual agonist of GLP-1Rs and neuropeptide Y2 receptors (Y2Rs) that attenuates fentanyl taking and seeking at doses that do not produce malaise-like effects in opioid-experienced rats. Whether activating Y2Rs alone is sufficient to reduce opioid taking and seeking, however, is not known. Here, we investigated the efficacy of the Y2R ligand PYY

Indexed as

FentanylOpioid-Related DisordersAnalgesics, OpioidAnimalsHumansMaleRatsRats, Sprague-DawleyReinforcement, PsychologySelf AdministrationAnalgesics, OpioidFentanylGLP-1OpioidPYY(3-36)RelapseSelf-administrationVTAY2R

Identifiers

PMID37572954
PMCPMC10528880
OpenAlexW4385737470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.